Literature DB >> 18410283

Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.

Beate Appenrodt1, Andrea Wolf, Frank Grünhage, Jonel Trebicka, Michael Schepke, Christian Rabe, Frank Lammert, Tilman Sauerbruch, J Heller.   

Abstract

BACKGROUND/AIMS: Large-volume paracentesis in patients with cirrhosis and ascites induces arterial vasodilatation and decreases effective arterial blood volume, termed paracentesis-induced circulatory dysfunction (PICD), which can be prevented by costly intravenous albumin. Vasoconstrictors, e.g. terlipressin, may also prevent PICD. The aim was to compare the less expensive vasoconstrictor midodrine, an alpha-adrenoceptor agonist, with albumin in preventing PICD.
METHODS: Twenty-four patients with cirrhosis and ascites were randomly assigned to be treated with either midodrine (n=11) (12.5 mg three times per day; over 2 days) or albumin (n=13) (8 g/L of removed ascites) after large-volume paracentesis. Effective arterial blood volume was assessed indirectly by measuring plasma renin and aldosterone concentration on days 0 and 6 after paracentesis; renal function and haemodynamic changes were also measured. PICD was defined as an increase in plasma renin concentration on day 6 by more than 50% of the baseline value.
RESULTS: PICD developed in six patients of the midodrine group (60%) and in only four patients (31%) of the albumin group. Six days after paracentesis, the aldosterone concentration increased significantly in the midodrine group, but not in the albumin group.
CONCLUSIONS: This pilot study suggests that midodrine is not as effective as albumin in preventing circulatory dysfunction after large-volume paracentesis in patients with cirrhosis and ascites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410283     DOI: 10.1111/j.1478-3231.2008.01734.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  18 in total

1.  What is the Role of Midodrine in Patients with Decompensated Cirrhosis?

Authors:  Klara Werling; Naga Chalasani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

2.  Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes.

Authors:  Kara B Johnson; Jessica L Mueller; Tracey G Simon; Hui Zheng; Lindsay Y King; Robert S Makar; Debra A Gervais; Raymond T Chung
Journal:  Dig Dis Sci       Date:  2015-02-28       Impact factor: 3.199

3.  The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.

Authors:  Khurram Bari; Cecilia Miñano; Martha Shea; Irteza B Inayat; Hashem J Hashem; Hochong Gilles; Douglas Heuman; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-16       Impact factor: 11.382

Review 4.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

Review 5.  Management of ascites.

Authors:  Fedja A Rochling; Rowen K Zetterman
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

Review 7.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 8.  Kidneys in chronic liver diseases.

Authors:  Marek Hartleb; Krzysztof Gutkowski
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

9.  Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.

Authors:  Hiang Keat Tan; Paul Damien James; Florence Wong
Journal:  Dig Dis Sci       Date:  2016-04-05       Impact factor: 3.199

10.  AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Giancarlo M Liumbruno; Francesco Bennardello; Pierluigi Piccoli; Claudio Velati
Journal:  Blood Transfus       Date:  2016-01       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.